CN103313714A - 地塞米松组合治疗 - Google Patents

地塞米松组合治疗 Download PDF

Info

Publication number
CN103313714A
CN103313714A CN2011800544683A CN201180054468A CN103313714A CN 103313714 A CN103313714 A CN 103313714A CN 2011800544683 A CN2011800544683 A CN 2011800544683A CN 201180054468 A CN201180054468 A CN 201180054468A CN 103313714 A CN103313714 A CN 103313714A
Authority
CN
China
Prior art keywords
amount
compound
dexamethasone
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800544683A
Other languages
English (en)
Chinese (zh)
Inventor
易庆
郑宇欢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103313714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN103313714A publication Critical patent/CN103313714A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800544683A 2010-11-12 2011-11-11 地塞米松组合治疗 Pending CN103313714A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41326010P 2010-11-12 2010-11-12
US61/413,260 2010-11-12
US42008910P 2010-12-06 2010-12-06
US61/420,089 2010-12-06
PCT/US2011/060297 WO2012065021A1 (en) 2010-11-12 2011-11-11 Dexamethasone combination therapy

Publications (1)

Publication Number Publication Date
CN103313714A true CN103313714A (zh) 2013-09-18

Family

ID=45094245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800544683A Pending CN103313714A (zh) 2010-11-12 2011-11-11 地塞米松组合治疗

Country Status (11)

Country Link
US (1) US20130310352A1 (https=)
EP (1) EP2637665B1 (https=)
JP (1) JP2013542262A (https=)
KR (1) KR20140009222A (https=)
CN (1) CN103313714A (https=)
AU (1) AU2011326394A1 (https=)
BR (1) BR112013011728A2 (https=)
CA (1) CA2816601A1 (https=)
MX (1) MX2013005271A (https=)
RU (1) RU2013126798A (https=)
WO (1) WO2012065021A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315260A (zh) * 2019-12-02 2022-11-08 新基公司 治疗癌症的疗法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101389622A (zh) * 2006-01-20 2009-03-18 诺瓦提斯公司 用作pi-3激酶抑制剂的嘧啶衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101389622A (zh) * 2006-01-20 2009-03-18 诺瓦提斯公司 用作pi-3激酶抑制剂的嘧啶衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURGER,MATTHEW T ET AL.: "Discovery of BKM120,a pan class I PI3 kinase inhibitor in phase I/II clinical trials", 《ABSTRACTS OF PAPERS，240TH ACS NATIONAL MEETING 》 *
WALSH K J等: "PI3k Inhibitors inhibit lymphoma growth by downregulation of MYC-Dependent proliferation", 《BLOOD》 *
沈云峰等: "持续小剂量地塞米松加沙立度胺治疗难治性多发性骨髓瘤的临床疗效观察", 《临床血液学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315260A (zh) * 2019-12-02 2022-11-08 新基公司 治疗癌症的疗法

Also Published As

Publication number Publication date
US20130310352A1 (en) 2013-11-21
MX2013005271A (es) 2013-09-26
RU2013126798A (ru) 2014-12-20
BR112013011728A2 (pt) 2016-08-16
KR20140009222A (ko) 2014-01-22
WO2012065021A1 (en) 2012-05-18
EP2637665A1 (en) 2013-09-18
EP2637665B1 (en) 2015-04-08
JP2013542262A (ja) 2013-11-21
CA2816601A1 (en) 2012-05-18
AU2011326394A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
RU2726367C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
US20220088029A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
US20140051662A1 (en) Treatment of multiple myeloma with masitinib
RU2731908C2 (ru) Композиции апилимода и способы его использования при лечениии меланомы
RU2630975C2 (ru) Режим дозирования pi-3 киназы
CN102065865B (zh) 多发性骨髓瘤治疗
KR20150081344A (ko) 조합 요법
CN107249638A (zh) 阿匹莫德用于治疗肾癌
AU2006259638A1 (en) Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
CN118574617A (zh) 使用ptpn11抑制剂和kras g12c抑制剂的组合疗法
WO2015075165A1 (en) Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
EP2637665B1 (en) Dexamethasone combination therapy
ES2644216B1 (es) Derivados del indazol para el tratamiento del gammapatías monoclonales.
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
RU2754131C1 (ru) Комбинированная терапия ингибитором ezh2
KR102363043B1 (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP2023537290A (ja) 癌を処置するためのＢｃｌ－２阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物
RU2850269C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
CA2617979A1 (en) Combination of a pyrimydlaminobenzamide tyrosine kinase inhibitor and a histone deacetylase inhibitor
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
NZ722491B2 (en) Apilimod compositions and methods for using same
NZ722491A (en) Apilimod compositions and methods for using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130918